文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

免疫调节剂治疗的银屑病患者对BNT162b2疫苗的抗体反应。

Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.

作者信息

Pavlotsky Felix, Segal Zvi, Barzilai Aviv

机构信息

Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Sackler Faculty of Medicine, Tel Aviv University, Israel.

出版信息

J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):24-28. doi: 10.1177/24755303211056059. Epub 2021 Nov 12.

DOI:10.1177/24755303211056059
PMID:39296727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11361508/
Abstract

BACKGROUND: Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce. OBJECTIVE: This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients. METHODS: BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls. RESULTS: Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group. CONCLUSIONS: Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.

摘要

背景：关于接受免疫调节药物治疗的银屑病患者中抗新冠病毒疫苗疗效的数据稀缺。 目的：本研究旨在检测这些患者接种BNT162b2疫苗后抗体阳性反应率。 方法：接种BNT162b2疫苗且接受免疫调节剂治疗的银屑病患者在接种第二剂疫苗后，通过雅培Architect或贝克曼库尔特对其针对新冠病毒刺突蛋白S的IgG抗体进行血清学检测。水平≥1 S1单位/毫升（S/ml）和>150任意单位/毫升（AU/ml）分别被视为抗体阳性反应。根据患者特征进一步分析抗体水平，并与医护人员对照组进行比较。 结果：51例患者中有49例出现抗体阳性反应。总体而言，接受免疫调节药物治疗的患者抗体水平与对照组相似。 结论：在绝大多数情况下，接受免疫调节剂治疗的银屑病患者似乎对完整的BNT162b2疫苗接种产生阳性抗体反应。

相似文献

[1]
Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.

J Psoriasis Psoriatic Arthritis. 2022-1

[2]
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.

Lancet Haematol. 2021-8

[3]
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.

Front Immunol. 2022

[4]
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors.

Clin Exp Rheumatol. 2023-1

[5]
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.

Vaccine. 2022-9-9

[6]
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.

Lancet Respir Med. 2021-9

[7]
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.

RMD Open. 2022-1

[8]
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.

Microbiol Spectr. 2021-12-22

[9]
Investigation of Anti-SARS-CoV-2-specific IgG Levels in Breast Milk after Vaccination or COVID-19 Infection.

Am J Perinatol. 2024-5

[10]
Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.

Vaccine. 2022-5-9

引用本文的文献

[1]
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis.

Acta Derm Venereol. 2024-5-2

[2]
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.

Front Immunol. 2024

本文引用的文献

[1]
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.

Lancet Rheumatol. 2021-9

[2]
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.

Ann Rheum Dis. 2021-10

[3]
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Nat Med. 2021-7

[4]
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.

Ann Rheum Dis. 2021-10

[5]
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.

Ann Rheum Dis. 2021-10

[6]
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Gut. 2021-5

[7]
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.

JAMA. 2021-5-4

[8]
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

N Engl J Med. 2021-4-15

[9]
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.

Lancet. 2021-3-6

[10]
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.

J Am Acad Dermatol. 2021-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索